FrancophonIA/ELRC3.0 huggingface dataset:
English: Investigational studies have shown that CKD patients not on dialysis treated with cinacalcet have an increased risk for hypocalcaemia (serum calcium levels < 8.4 mg/dl [2.1 mmol/l]) compared with cinacalcet-treated CKD patients on dialysis, which may be due to lower baseline calcium levels and/or the presence of residual kidney function.
Croatian: Ispitivanja su pokazala da bolesnici s kroničnom bolesti bubrega koji nisu na dijalizi, a liječeni su sinakalcetom, imaju povećan rizik za hipokalcemiju (vrijednost serumskog kalcija < 8,4 mg/dl [2,1 mmol/l]) u usporedbi sa sinakalcetom liječenim bolesnicima s kroničnom bolesti bubrega koji su na dijalizi, što može biti posljedica manje početne vrijednosti kalcija i/ili postojeće ostatne funkcije bubrega.
English: Serum calcium should be measured within 1 week after initiation or dose adjustment of cinacalcet.
Croatian: Serumski kalcij treba kontrolirati unutar 1 tjedna nakon početka primjene ili prilagodbe doze cinakalceta.
English: • If you start to get numbness or tingling around the mouth, muscle aches or cramps and seizures.
Croatian: • Ako osjetite utrnulost ili trnce oko usta, bol u mišićima ili grčeve i napadaje.
English: PTH should be measured 1 to 4 weeks after initiation or dose adjustment of cinacalcet.
Croatian: Vrijednosti PTH-a trebaju se kontrolirati 1 do 4 tjedna nakon započete terapije ili prilagodbe doze ccinakalceta.
English: Dizziness and seizures have been reported by patients taking cinacalcet.
Croatian: Omaglica i napadaji prijavljeni su od bolesnika liječenih sinakalcetom.
English: • liver problems;
Croatian: • problema s jetrom;
English: There have been reports of idiosyncratic cases of hypotension and/or worsening heart failure in cinacalcet-treated patients with impaired cardiac function in post-marketing safety surveillance, the frequencies of which cannot be estimated from available data.
Croatian: Tijekom praćenja sigurnosti lijeka nakon stavljanja u promet zabilježeni su idiosinkrazijski slučajevi hipotenzije i/ili pogoršanja zatajenja srca u bolesnika liječenih sinakalcetom s oštećenom srčanom funkcijom, čija se učestalost ne može procijeniti iz dostupnih podataka.
English: Each film-coated tablet contains 30 mg, 60 mg or 90 mg of cinacalcet (as hydrochloride).
Croatian: Jedna filmom obložena tableta sadrži 30 mg, 60 mg ili 90 mg cinakalceta (u obliku cinakalcetklorida).
English: It is not known whether cinacalcet is excreted in human milk.
Croatian: Nije poznato izlučuje li se sinakalcet u majčino mlijeko u ljudi.
English: Cinacalcet Mylan 30 mg, 60 mg, 90 mg film-coated tablets are green, oval, biconvex, bevelled edge tablets marked with M on one side of the tablet and CI30, CI60 or CI90 on the other side.
Croatian: Cinacalcet Mylan 30 mg, 60 mg ili 90 mg su zelene, filmom obložene, ovalne, bikonveksne tablete s ukošenim rubom i oznakom „M“ na jednoj i „CI30“ „CI60“ ili „CI90“ na drugoj strani.
English: The active substance is cinacalcet.
Croatian: Djelatna tvar je sinakalcet.
English: HDPE bottle with polypropylene (PP) screw cap closure with induction sealing liner containing 100 tablets.
Croatian: Boca od polietilena visoke gustoće s polipropilenskim navojnim zatvaračem sa zaštitnom folijom koja sadrži 100 tableta.
English: Cinacalcet Mylan 30 mg, 60 mg, 90 mg film-coated tablets are available in blister packs of 28 tablets and perforated unit dose blister packs of 28 x 1, 30 x 1 and 84 x 1 tablets.
Croatian: Cinacalcet Mylan 30 mg, 60 mg ili 90 mg filmom obložene tablete dostupne su u blister pakiranjima od 28 tableta i perforiranim blisterima djeljivima na jedinične doze, koji sadrže 28 x 1, 30 x 1 i 84 x 1 tabletu.
English: • seizures (fits or convulsions).
Croatian: • napadaje (konvulzije).
English: Worsening heart failure* QT prolongation and ventricular arrhythmia secondary to hypocalcaemia*
Croatian: • produljenje QT intervala i ventrikularna aritmija uzrokovana hipokalcemijom*
English: These studies show that CKD patients not undergoing dialysis treated with cinacalcet have an increased risk for hypocalcaemia compared with cinacalcet-treated ESRD patients receiving dialysis, which may be due to lower baseline calcium levels and/or the presence of residual kidney function.
Croatian: Ova ispitivanja su pokazala da kod bolesnika s kroničnom bolesti bubrega koji nisu na dijalizi, a liječeni su sinakalcetom, postoji povećan rizik hipokalcemije, u usporedbi s bolesnicima sa završnim stadijem bolesti bubrega liječenih sinakalcetom koji su na dijalizi, što može biti zbog niže početne vrijednosti kalcija i/ili postojeće ostatne bubrežne funkcije.
English: Parathyroid carcinoma and primary hyperparathyroidism:
Croatian: Paratireoidni karcinom i primarni hiperparatireoidizam
English: Cinacalcet Mylan 30 mg film-coated tablets Cinacalcet Mylan 60 mg film-coated tablets Cinacalcet Mylan 90 mg film-coated tablets cinacalcet
Croatian: Cinacalcet Mylan 30 mg filmom obložene tablete Cinacalcet Mylan 60 mg filmom obložene tablete Cinacalcet Mylan 90 mg filmom obložene tablete sinakalcet
English: How to store Cinacalcet Mylan
Croatian: Kako čuvati Cinacalcet Mylan
English: Cinacalcet was administered at doses ranging from 30 mg twice daily to 90 mg four times daily.
Croatian: Doza cinakalceta bila je između 30 mg dva puta dnevno i 90 mg četiri puta dnevno.
English: • parathyroid carcinoma.
Croatian: • karcinomom paratireoidnih žlijezda
English: • low calcium levels in the blood (hypocalcaemia).
Croatian: • niske razine kalcija u krvi (hipokalcemija)
English: After titration to the maximum dose of cinacalcet, serum calcium should be periodically monitored; if clinically relevant reductions in serum calcium are not maintained, discontinuation of cinacalcet therapy should be considered (see section 5.1).
Croatian: Ako se ne postigne klinički značajno smanjenje serumskog kalcija, treba razmotriti prekid terapije sinakalcetom (vidjeti dio 5.1).
English: Secondary hyperparathyroidism, parathyroid carcinoma and primary hyperparathyroidism Based on available data from patients receiving cinacalcet in placebo controlled studies and single-arm studies the most commonly reported adverse reactions were nausea and vomiting.
Croatian: Na temelju dostupnih podataka od bolesnika koji su primali sinakalcet u placebom kontroliranim ispitivanjima i ispitivanjima na jednoj skupini, najčešće zabilježene nuspojave bile su mučnina i povraćanje.
English: Hepatic insufficiency
Croatian: Jetrena insuficijencija
English: B. PACKAGE LEAFLET
Croatian: b) Tablični prikaz nuspojava
English: SN: NN:
Croatian: PC: SN:
English: Puh/Tel: + 358 20 720 9555
Croatian: Suomi/Finland Mylan Finland OY Puh/Tel: + 358 20 720 9555
English: • indigestion (dyspepsia)
Croatian: • slabost (astenija)
English: • seizures (convulsions or fits)
Croatian: • napadaji (konvulzije)
English: PTH should be monitored approximately every 1-3 months during maintenance.
Croatian: Za vrijeme terapije održavanja, vrijednosti PTH-a treba kontrolirati svakih mjesec dana do tri mjeseca.
English: How to take Cinacalcet Mylan
Croatian: Kako uzimati lijek Cinacalcet Mylan
English: • diarrhoea
Croatian: • hipotenzija
English: If you are being treated for secondary hyperparathyroidism The recommended starting dose for Cinacalcet Mylan is 30 mg (one tablet) once per day.
Croatian: Preporučena početna doza lijeka Cinacalcet Mylan je 30 mg (jedna tableta) jednom dnevno.
English: • if you start or stop smoking, as this may affect the way Cinacalcet Mylan works.
Croatian: Tijekom liječenja lijekom Cinacalcet Mylan obavijestite svojeg liječnika: • ako ste počeli ili prestali pušiti, jer to može utjecati na djelovanje lijeka Cinacalcet Mylan.
English: Calcium-containing phosphate binders, vitamin D sterols and/or adjustment of dialysis fluid calcium concentrations can be used to raise serum calcium according to clinical judgment.
Croatian: D i/ili se može prilagoditi koncentracija kalcija u otopini za dijalizu, sukladno kliničkoj procjeni.
English: Life threatening events and fatal outcomes associated with low calcium levels (hypocalcaemia) have been reported in patients treated with cinacalcet.
Croatian: U bolesnika liječenih sinakalcetom zabilježeni su događaji opasni po život i smrtni ishodi povezani s niskim razinama kalcija (hipokalcemijom).
English: • a medicine used to relieve cough (dextromethorphan)
Croatian: • lijek za ublažavanje kašlja (dekstrometorfan);
English: Cinacalcet Mylan 30 mg film-coated tablets Each film-coated tablet contains 30 mg of cinacalcet (as hydrochloride).
Croatian: Cinacalcet Mylan 30 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 30 mg ccinakalceta (u obliku ccinakalcetklorida).
English: Cinacalcet Mylan 90 mg film-coated tablets Each film-coated tablet contains 90 mg of cinacalcet (as hydrochloride).
Croatian: Cinacalcet Mylan 90 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 90 mg ccinakalceta (u obliku ccinakalcetklorida).
English: EU/1/15/1054/001 EU/1/15/1054/002 EU/1/15/1054/003 EU/1/15/1054/004 EU/1/15/1054/005 EU/1/15/1054/006 EU/1/15/1054/007 EU/1/15/1054/008 EU/1/15/1054/009 EU/1/15/1054/010 EU/1/15/1054/011 EU/1/15/1054/012
Croatian: EU/1/15/1054/004 EU/1/15/1054/005 EU/1/15/1054/006 EU/1/15/1054/007 EU/1/15/1054/008 EU/1/15/1054/009 EU/1/15/1054/010 EU/1/15/1054/011 EU/1/15/1054/012 EU/1/15/1054/013
English: Protein binding of cinacalcet is not affected by impaired hepatic function.
Croatian: Oštećenje funkcije jetre ne mijenja vezanje cinakalceta za proteine.
English: Cinacalcet Mylan 60 mg film-coated tablets Each film-coated tablet contains 60 mg of cinacalcet (as hydrochloride).
Croatian: Cinacalcet Mylan 60 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 60 mg ccinakalceta (u obliku ccinakalcetklorida).
English: Each film-coated tablet contains 30 mg of cinacalcet (as hydrochloride).
Croatian: Jedna filmom obložena tableta sadrži 30 mg cinakalceta (u obliku cinakalcetklorida).
English: • abdominal pain, abdominal pain - upper
Croatian: • bol u gornjem dijelu abdomena
English: Each film-coated tablet contains 90 mg of cinacalcet (as hydrochloride).
Croatian: Jedna filmom obložena tableta sadrži 90 mg cinakalceta (u obliku cinakalcetklorida).
English: Each film-coated tablet contains 60 mg of cinacalcet (as hydrochloride).
Croatian: Jedna filmom obložena tableta sadrži 60 mg cinakalceta (u obliku cinakalcetklorida).
English: Cinacalcet Mylan 30 mg film-coated tablets.
Croatian: Cinacalcet Mylan 30 mg filmom obložene tablete.
English: Cinacalcet Mylan 60 mg film-coated tablets.
Croatian: Cinacalcet Mylan 60 mg filmom obložene tablete.
English: Cinacalcet Mylan 90 mg film-coated tablets.
Croatian: Cinacalcet Mylan 90 mg filmom obložene tablete.
English: 12.5 mm x 8.0 mm, green, film-coated, oval, biconvex, bevelled edge tablet debossed with M on one side of the tablet and CI60 on the other side.
Croatian: Zelena filmom obložena, ovalna, bikonveksna tableta veličine 12,5 mm x 8,0 mm s ukošenim rubom i utisnutom oznakom “M” na jednoj strani tablete i “CI60” na drugoj strani.
English: If you are being treated for parathyroid cancer or primary hyperparathyroidism The recommended starting dose for Cinacalcet Mylan is 30 mg (one tablet) twice per day.
Croatian: Preporučena početna doza lijeka Cinacalcet Mylan je 30 mg (jedna tableta) dva puta dnevno.
English: 10.0 mm x 6.4 mm, green, film-coated, oval, biconvex, bevelled edge tablet debossed with M on one side of the tablet and CI30 on the other side.
Croatian: Zelena filmom obložena, ovalna, bikonveksna tableta veličine 10,0 mm x 6,4 mm s ukošenim rubom i utisnutom oznakom “M” na jednoj strani tablete i “CI30” na drugoj strani.
English: Hypromellose
Croatian: • hipokalcemija
English: 14.3 mm x 9.0 mm, green, film-coated, oval, biconvex, bevelled edge tablet debossed with M on one side of the tablet and CI90 on the other side.
Croatian: Zelena filmom obložena, ovalna, bikonveksna tableta veličine 14,3 mm x 9,0 mm s ukošenim rubom i utisnutom oznakom “M” na jednoj strani tablete i “CI90” na drugoj strani.
English: • muscle spasms
Croatian: • omaglica
English: Cinacalcet Mylan 30 mg film-coated tablets
Croatian: Cinacalcet Mylan 30 mg filmom obložene tablete
English: Cinacalcet Mylan 60 mg film-coated tablets
Croatian: Cinacalcet Mylan 60 mg filmom obložene tablete
English: Cinacalcet Mylan 90 mg film-coated tablets
Croatian: Cinacalcet Mylan 90 mg filmom obložene tablete
English: Following careful benefit/risk assessment, a decision should be made to discontinue either breast-feeding or treatment with Cinacalcet Mylan.
Croatian: Odluku o prekidu dojenja ili liječenja lijekom Cinacalcet Mylan treba donijeti na osnovi pomne procjene koristi i rizika.
English: Cinacalcet Mylan 30 mg film-coated tablets cinacalcet
Croatian: Cinacalcet Mylan 30 mg filmom obložene tablete sinakalcet
English: Tel: + 34 900 102 712
Croatian: Mylan Pharmaceuticals, S.L. Tel: + 34 900 102 712
English: Dyspepsia Diarrhoea Abdominal pain
Croatian: Karcinom paratireoidnih žlijezda i primarni hiperparatireoidizam
English: Cinacalcet Mylan 60 mg film-coated tablets cinacalcet
Croatian: Cinacalcet Mylan 60 mg filmom obložene tablete sinakalcet
English: Cinacalcet Mylan 90 mg film-coated tablets cinacalcet
Croatian: Cinacalcet Mylan 90 mg filmom obložene tablete sinakalcet
English: The recommended dose is two inhalations twice a day.
Croatian: Preporučenu dozu čine dvije inhalacije dva puta na dan.
English: This medicine is the same as Trimbow, which is already authorised in the EU.
Croatian: Ovaj lijek isti je kao Trimbow, lijek koji je već odobren u EU-u.
English: Further information on Riarify can be found on the Agency's website: https://www.ema.europa.eu/en/medicines/human/EPAR/riarify-previously-chf-5993-chiesifarmaceutici-spa.
Croatian: Više informacija o lijeku Riarify nalazi se na internetskim stranicama Agencije: https://www.ema.europa.eu/en/medicines/human/EPAR/riarify-previously-chf-5993-chiesifarmaceutici-spa.
English: Riarify received a marketing authorisation valid throughout the EU on 23 April 2018.
Croatian: Lijek Riarify dobio je odobrenje za stavljanje u promet koje je na snazi u EU-u od 23. travnja 2018.
English: The company that makes Trimbow has agreed that its scientific data can be used for Riarify (‘informed consent').
Croatian: Tvrtka koja proizvodi Trimbow pristala je da se njezini znanstveni podatci upotrebljavaju za lijek Riarify („informirani pristanak”).
English: Formoterol is a long-acting beta-2 agonist.
Croatian: Formoterol je dugodjelujući beta-2 agonist.
English: It works in a similar way to naturally occurring corticosteroid hormones, reducing the activity of the immune system.
Croatian: On djeluje na sličan način kao prirodni kortikosteroidni hormoni, odnosno smanjuje aktivnost imunosnog sustava.
English: Other information about Riarify
Croatian: Ostale informacije o lijeku Riarify
English: What is Riarify and what is it used for?
Croatian: Što je Riarify i za što se primjenjuje?
English: What measures are being taken to ensure the safe and effective use of Riarify?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Riarify?
English: Riarify (beclomethasone / formoterol / glycopyrronium bromide)
Croatian: Riarify (beklometazon/formoterol/glikopironijev bromid)
English: Side effects reported with Riarify are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Riarify pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: The European Medicines Agency therefore decided that Riarify's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove stoga je zaključila da koristi od lijeka Riarify nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Riarify have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Riarify nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: As for all medicines, data on the use of Riarify is continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Riarify kontinuirano se prate.
English: An overview of Riarify and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Riarify i zašto je odobren u EU-u
English: What are the risks associated with Riarify?
Croatian: Koji su rizici povezani s lijekom Riarify?
English: Beta-2 agonists and muscarinic receptor antagonists help to widen the airways; corticosteroids reduce inflammation in the airways and lungs.
Croatian: Beta-2 agonisti i antagonisti muskarinskih receptora pomažu u širenju dišnih putova, a kortikosteroidi smanjuju upalu u dišnim putovima i plućima.
English: For more information about using Riarify, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Riarify pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
English: Riarify is available as a liquid in a portable inhaler device.
Croatian: Lijek Riarify dostupan je kao tekućina u prijenosnom inhalatoru.
English: Patients should be shown how to use the inhaler correctly by a doctor or another healthcare professional, who should also regularly check that the patient's inhalation technique is correct.
Croatian: Liječnik ili neki drugi zdravstveni radnik trebaju pokazati bolesnicima kako se ispravno koristiti inhalatorom i redovito provjeravati primjenjuje li bolesnik ispravnu inhalacijsku tehniku.
English: It opens the airways by blocking muscarinic receptors in muscle cells in the lungs.
Croatian: On otvara dišne putove blokirajući muskarinske receptore u mišićnim stanicama u plućima.
English: Beclometasone belongs to anti-inflammatory medicines known as corticosteroids.
Croatian: Beklometazon spada u skupinu protuupalnih lijekova koji se nazivaju kortikosteroidi.
English: In the first study lasting a year, after 26 weeks of treatment Riarify improved patients' FEV1 (the maximum volume of air a person can breathe out in one second) by 82 ml before a dose and 261 ml after a dose.
Croatian: U prvom ispitivanju koje je trajalo godinu dana, nakon 26 tjedana terapije lijekom Riarify poboljšao se FEV1 (najveći volumen zraka koji osoba može izdahnuti u jednoj sekundi) bolesnika za 82 ml prije uzimanja doze i za 261 ml nakon uzimanja doze.
English: Why is Riarify authorised in the EU?
Croatian: Zašto je lijek Riarify odobren u EU-u?
English: No major safety concerns have been reported with Riarify, with side effects being manageable and similar to other COPD medicines.
Croatian: Nije prijavljeno nijedno ozbiljnije sigurnosno pitanje u vezi s lijekom Riarify, a nuspojave se mogu kontrolirati i slične su nuspojavama ostalih lijekova za liječenje KOPB-a.
English: Side effects with Riarify include oral candidiasis (a fungal infection of the mouth caused by a yeast called Candida), muscle spasms and dry mouth.
Croatian: U nuspojave lijeka Riarify ubrajaju se oralna kandidijaza (gljivična infekcija usta uzrokovana gljivicom Candida), mišićni grčevi i suha usta.
English: Riarify has been shown to be effective at relieving symptoms of COPD in three main studies involving over 5,500 patients whose symptoms were not controlled well enough either by combinations of two other COPD medicines or by a muscarinic receptor antagonist alone.
Croatian: Utvrđeno je da Riarify učinkovito ublažava simptome KOPB-a u trima glavnim ispitivanjima kojima je obuhvaćeno više od 5 500 bolesnika čiji simptomi nisu bili odgovarajuće kontrolirani ni kombinacijom drugih dvaju lijekova za liječenje KOPB-a ni monoterapijom antagonista muskarinskih receptora.
English: Glycopyrronium bromide is a long-acting muscarinic receptor antagonist.
Croatian: Glikopironijev bromid dugodjelujući je antagonist muskarinskih receptora.
English: By comparison, the FEV1 increased by 1 and 145 ml before and after dosing in patients treated with a medicine containing only 2 of the active substances found in Riarify (beclometasone plus formoterol).
Croatian: Za usporedbu, FEV1 se povećao za 1 ml prije, odnosno 145 ml nakon uzimanja doze u bolesnika liječenih lijekom koji je sadržavao samo dvije djelatne tvari lijeka Riarify (beklometazon i formoterol).
English: Riarify is a medicine used in adults to relieve the symptoms of moderate to severe chronic obstructive pulmonary disease (COPD).
Croatian: Riarify je lijek koji se primjenjuje za ublažavanje simptoma umjerene do teške kronične opstruktivne plućne bolesti (KOPB) u odraslih osoba.
English: Riarify is used for maintenance (continuing) treatment in patients whose disease is not adequately controlled despite treatment with a combination of two COPD medicines consisting of a long-acting beta-2 agonist plus either an inhaled corticosteroid or a long-acting muscarinic receptor antagonist.
Croatian: Riarify se upotrebljava kao (redovita) terapija održavanja u bolesnika čija bolest nije odgovarajuće kontrolirana unatoč liječenju kombinacijom dvaju lijekova za KOPB koja se sastoji od dugodjelujućeg beta-2 agonista u kombinaciji s inhalacijskim kortikosteroidom ili dugodjelujućim antagonistom muskarinskih receptora.
English: Riarify contains the active substances beclometasone, formoterol and glycopyrronium bromide.
Croatian: Riarify sadrži djelatne tvari beklometazon, formoterol i glikopironijev bromid.
English: It attaches to receptors (targets) known as beta-2 receptors in the muscles of the airways.
Croatian: Djeluje tako da se spaja na beta-2 receptore, odnosno receptore (ciljna mjesta) koji se nalaze u mišićima dišnih putova.
English: In the second study lasting a year, patients treated with Riarify had 20% fewer exacerbations (flareups of symptoms) per year than patients treated with tiotropium (a long-acting muscarinic receptor antagonist).
Croatian: U drugom ispitivanju koje je trajalo godinu dana, bolesnici liječeni lijekom Riarify imali su 20 % manje pogoršanja bolesti (razbuktavanja simptoma) godišnje nego bolesnici liječeni tiotropijem (dugodjelujućim antagonistom muskarinskih receptora).
English: What benefits of Riarify have been shown in studies?
Croatian: Koje su koristi od lijeka Riarify utvrđene u ispitivanjima?
English: In the third study lasting a year, patients treated with Riarify had 15% fewer exacerbations a year than patients treated with a combination of indacaterol (a long-acting beta-2 agonist) and glycopyrronium bromide.
Croatian: U trećem ispitivanju koje je trajalo godinu dana, bolesnici liječeni lijekom Riarify imali su 15 % manje pogoršanja bolesti godišnje od bolesnika liječenih kombinacijom indakaterola (dugodjelujućeg beta-2 agonista) i glikopironijeva bromida.
English: By attaching to these receptors, it causes the muscles to relax, which keeps the airways open and helps with the patient's breathing.
Croatian: Spajanjem na te receptore on uzrokuje opuštanje mišića, što održava dišne putove prohodnima i pomaže bolesniku pri disanju.
English: In this study, Riarify was as effective as tiotropium plus a combination of beclometasone and formoterol at reducing the number of exacerbations.
Croatian: U tom je ispitivanju lijek Riarify bio jednako učinkovit u smanjenju broja pogoršanja bolesti kao tiotropij u kombinaciji s beklometazonom i formoterolom.
English: Because these receptors help control the contraction of the airway muscles, blocking them causes the muscles to relax, helping to keep the airways open and allowing the patient to breathe more easily.
Croatian: Budući da ti receptori doprinose kontroli stezanja mišića dišnih putova, njihovim blokiranjem mišići se opuštaju, čime se dišni putovi održavaju prohodnima, a bolesnik lakše diše.
English: This leads to a reduction in the release of substances involved in the inflammation process, such as histamine, thereby helping to keep the airways clear and allowing the patient to breathe more easily.
Croatian: To dovodi do smanjenog otpuštanja tvari koje sudjeluju u procesu upale, poput histamina, čime se dišni putovi kontinuirano održavaju prohodnima i bolesnik lakše diše.